Emerging therapeutic approaches in graves’ ophthalmopathy: an update on pharmacological interventions
Graves’ ophthalmopathy (GO), also known as thyroid eye disease (TED), is the most common extrathyroidal manifestation of Graves’ disease and a leading cause of visual morbidity. The disease primarily affects the orbital tissue and is characterized by inflammation, expansion of extraocular muscles, a...
Saved in:
| Main Authors: | Lin Wang, Linlin Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1647602/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Teprotumumab and sensorineural hearing loss: a propensity score-matched retrospective cohort study
by: Maxim John Levy Barnett, et al.
Published: (2025-07-01) -
Validation of Indonesian Graves’ Ophthalmopathy Quality of Life Questionnaire and Its Association with Clinical Activity and Severity of Graves’ Ophthalmopathy
by: Cecilia Anggraini, et al.
Published: (2025-01-01) -
Rituximab in the treatment of Graves’ disease and endocrine ophthalmopathy. Opportunities and limitations
by: T. S. Panevin, et al.
Published: (2023-10-01) -
Extraocular muscle index as a novel indicator of inflammatory condition in graves’ ophthalmopathy patients
by: Fangkun Wu, et al.
Published: (2025-05-01) -
An Update on Medical Management of Thyroid Eye Disease with Insights on Teprotumumab
by: Smriti Dabas, et al.
Published: (2023-07-01)